SFDA Employee Accused Of Bribery Totaling RMB 1.3 Million
This article was originally published in PharmAsia News
A Haidian court recently heard the case of an SFDA staff member accused of accepting bribes totaling RMB 1.3 million to accelerate drug approvals
You may also be interested in...
Officials explain how remote record reviews, site transfers and other factors can green-light approvals of drugs and biologics.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.